<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906395</url>
  </required_header>
  <id_info>
    <org_study_id>TOL2506A</org_study_id>
    <nct_id>NCT04906395</nct_id>
  </id_info>
  <brief_title>Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer</brief_title>
  <acronym>OVELIA</acronym>
  <official_title>Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tolmar Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tolmar Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to&#xD;
      suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The&#xD;
      study will also aim to assess administration of TOL2506 in men with HR+ breast cancer. Study&#xD;
      duration, for individual subjects, will be up to 57 weeks, including a Screening Period of up&#xD;
      to 9 weeks, a Treatment Period of 48 weeks, and an End of Study Visit (Visit 8, Week 48).&#xD;
      Eligible subjects will enter into the Treatment Period in 1 of 2 groups: those who will&#xD;
      receive tamoxifen concurrently with TOL2506 or those who will initiate therapy with an AI&#xD;
      (letrozole, anastrozole, or exemestane) beginning 6 weeks after the first administration of&#xD;
      TOL2506, upon confirmation that estradiol (E2) levels of &lt; 20 pg/mL have been achieved. After&#xD;
      Week 12, subjects will be allowed to switch from receiving an AI to receiving tamoxifen or&#xD;
      from tamoxifen to AI at the discretion of the Investigator. However, a switch is not&#xD;
      permitted 28 days prior to a dosing visit. At the end of the Treatment Period, subjects will&#xD;
      be eligible for compassionate use of TOL2506 (expanded access) until TOL2506 receives&#xD;
      marketing approval and is commercially available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suppression of ovarian function (E2 levels and menses status)</measure>
    <time_frame>6 weeks after the first administration of TOL2506</time_frame>
    <description>E2 levels &lt; 20 pg/mL at Week 6 and absence of menses after Week 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suppression of ovarian function overall (E2 and absence of menses; treatments pooled)</measure>
    <time_frame>Week 6 to Week 48</time_frame>
    <description>Percent of subjects with suppressed E2 and absence of menses in subjects treated with TOL2506 + endocrine therapy (tamoxifen or aromatase inhibitors) at every measurement from Week 6 to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of ovarian function overall (E2 and absence of menses; TOL2506 + tamoxifen)</measure>
    <time_frame>Week 6 to Week 48</time_frame>
    <description>Percent of subjects with suppressed E2 and absence of menses in subjects treated with TOL2506 + tamoxifen at every measurement from Week 6 to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of ovarian function overall (E2 and absence of menses; TOL2506 + aromatase inhibitor)</measure>
    <time_frame>Week 6 to Week 48</time_frame>
    <description>Percent of subjects with suppressed E2 and absence of menses in subjects treated with TOL2506 + aromatase inhibitor at every measurement from Week 6 to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of ovarian function at Weeks 12, 24, 36, and 48 (E2 and absence of menses + treatments pooled)</measure>
    <time_frame>Weeks 12, 24, 36, and 48</time_frame>
    <description>Percent of subjects with suppressed E2 &lt; 20 pg/mL and absence of menses in subjects treated with TOL2506 + endocrine therapy (tamoxifen or aromatase inhibitors) assessed individually at weeks 12, 24, 36 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of ovarian function at Weeks 12, 24, 36, and 48 (E2 and absence of menses; TOL2506 + tamoxifen)</measure>
    <time_frame>Weeks 12, 24, 36, and 48</time_frame>
    <description>Percent of subjects with suppressed E2 &lt; 20 pg/mL and absence of menses in subjects treated with TOL2506 + tamoxifen assessed individually at weeks 12, 24, 36 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of ovarian function at Weeks 12, 24, 36, and 48 (E2 and absence of menses; TOL2506 + aromatase inhibitor)</measure>
    <time_frame>Weeks 12, 24, 36, and 48</time_frame>
    <description>Percent of subjects with suppressed E2 &lt; 20 pg/mL and absence of menses in subjects treated with TOL2506 + aromatase inhibitor assessed individually at weeks 12, 24, 36 and 48</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Active Comparator: TOL2506</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TOL2506 in combinatination with standard endocrine therapy (Tamoxifen &amp; Aromatase Inhibitors)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOL2506</intervention_name>
    <description>Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.</description>
    <arm_group_label>Active Comparator: TOL2506</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>20 mg once daily or 10 mg 2 times daily - either tablet or solution</description>
    <arm_group_label>Active Comparator: TOL2506</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole Tablets</intervention_name>
    <description>One 2.5 mg tablet taken orally once daily</description>
    <arm_group_label>Active Comparator: TOL2506</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole Tablets</intervention_name>
    <description>One 1 mg tablet taken orally once daily</description>
    <arm_group_label>Active Comparator: TOL2506</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane Tablets</intervention_name>
    <description>One 25 mg tablet taken orally once daily</description>
    <arm_group_label>Active Comparator: TOL2506</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females&#xD;
&#xD;
               1. Able to understand the investigational nature of this study and provide written&#xD;
                  informed consent prior to the participation in the trial&#xD;
&#xD;
               2. Age 18 to 55, inclusive&#xD;
&#xD;
               3. Diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer (ER&gt;1% and/or,&#xD;
                  PR&gt;1%, HER2-negative per ASCO CAP guidelines)&#xD;
&#xD;
               4. Is a candidate for endocrine therapy + ovarian suppression&#xD;
&#xD;
               5. Is premenopausal at the time of study entry.&#xD;
&#xD;
                    -  E2 &gt; 30 pg/mL&#xD;
&#xD;
                    -  Follicle stimulating hormone (FSH) &lt; 40 IU/L&#xD;
&#xD;
                    -  Last menstrual period within the 3 months prior to first dose of TOL2506&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Females&#xD;
&#xD;
               1. Body mass index (BMI) &lt; 18.00 kg/m2 or &gt; 35.00 kg/m2&#xD;
&#xD;
               2. Breastfeeding&#xD;
&#xD;
               3. Life expectancy &lt; 12 months&#xD;
&#xD;
               4. Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3&#xD;
&#xD;
               5. Unacceptable hepatic function as determined by any of the following:&#xD;
&#xD;
                    1. Alanine aminotransferase (ALT) ≥ 2X upper limit of normal (ULN)&#xD;
&#xD;
                    2. Aspartate aminotransferase (AST) ≥ 2X ULN&#xD;
&#xD;
                    3. Bilirubin ≥ 2X ULN&#xD;
&#xD;
                    4. Alkaline phosphatase ≥ 2X ULN&#xD;
&#xD;
                    5. Severe hepatic impairment (Child-Pugh Class C)&#xD;
&#xD;
               6. Unacceptable renal function as determined by any of the following:&#xD;
&#xD;
                    1. Creatinine ≥ 3X ULN&#xD;
&#xD;
                    2. Creatinine clearance ≤ 30 mL/minute&#xD;
&#xD;
                    3. Creatinine clearance ≤ 60 mL/minute in subjects with bone density 1.5&#xD;
                       standard deviations below the young adult normal mean&#xD;
&#xD;
               7. History of significantly abnormal ECG or screening 12-lead ECG demonstrating any&#xD;
                  of the following:&#xD;
&#xD;
                    1. HR &gt; 100 BPM&#xD;
&#xD;
                    2. QRS &gt; 120 msec&#xD;
&#xD;
                    3. QTc &gt; 450 msec&#xD;
&#xD;
                    4. PR &gt; 220 msec&#xD;
&#xD;
               8. Prior (within 28 days prior to Day 0) and/or concomitant use of medications known&#xD;
                  to prolong the QT/QTc interval&#xD;
&#xD;
               9. Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg,&#xD;
                  fulvestrant), aromatase inhibitor, mammalian target of rapamycin (mTOR)&#xD;
                  inhibitors, or hormone replacement therapy within 3 months before breast cancer&#xD;
                  diagnosis&#xD;
&#xD;
              10. Prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer&#xD;
&#xD;
              11. History of treatment for osteopenia/osteoporosis&#xD;
&#xD;
              12. Prior or current use of drugs or supplements known to increase bone mineral&#xD;
                  density (ie, bisphosphonates, denosumab, teriparatide, abaloparatide,&#xD;
                  romosozumab, calcitonin, fluoride, strontium)&#xD;
&#xD;
              13. Low trauma fracture(s) occurring within 12 months prior to Screening (defined as&#xD;
                  a fracture that results from a fall from a standing height or less, excluding&#xD;
                  fingers, toes, face and skull)&#xD;
&#xD;
              14. Conditions that preclude bone mineral density measurement (lumbar spine/bilateral&#xD;
                  hip surgery with hardware in place, abdominal clips, umbilical ring [not willing&#xD;
                  to remove] or weight that exceeds the DEXA machine limitation)&#xD;
&#xD;
              15. Any other medical condition or serious illness, presence of a second malignancy&#xD;
                  under current treatment or follow-up, or the presence of clinically significant&#xD;
                  findings on the physical exam, laboratory testing, medical history (including&#xD;
                  conditions that may be associated with low bone mass), that in the opinion of the&#xD;
                  Investigator may interfere with trial conduct, subject safety, or interpretation&#xD;
                  of study results&#xD;
&#xD;
              16. Already receiving and/or previously received GnRH analogs within 1 year before&#xD;
                  breast cancer diagnosis&#xD;
&#xD;
              17. Psychiatric, addictive, or other disorders that would preclude study compliance&#xD;
&#xD;
              18. Use of medications that may impact subject safety and/or affect the PK of the&#xD;
                  drug and hormonal assessments including but not limited to:&#xD;
&#xD;
                    1. Oral or transdermal hormonal therapy within 30 days prior to Screening&#xD;
&#xD;
                    2. Estrogen, progesterone, or androgens within 30 days prior to Screening&#xD;
&#xD;
                    3. Hormonal contraceptives within 30 days prior to Screening&#xD;
&#xD;
                    4. Medications known to result in clinically important decreases in bone mass&#xD;
                       taken within 6 months prior to Screening&#xD;
&#xD;
              19. Known hypersensitivity, idiosyncratic, or allergic reactions to GnRH, GnRH&#xD;
                  agonist/analogs or to any of the components of the IP&#xD;
&#xD;
              20. Sexually active with a male partner and not willing to use non-hormonal&#xD;
                  contraceptive methods throughout the study&#xD;
&#xD;
              21. Is of childbearing potential with a positive serum pregnancy test at Screening or&#xD;
                  urine pregnancy test at Day 0&#xD;
&#xD;
              22. Exposure to any investigational agent within 30 days prior to the first dose of&#xD;
                  TOL2506&#xD;
&#xD;
        See contact information to obtain inclusion/exclusion criteria for males&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E P Hamilton</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J Morrison</last_name>
    <phone>949-224-2856</phone>
    <email>jmorrison@clinipace.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>C Schany</last_name>
    <phone>936-276-6294</phone>
    <phone_ext>6294</phone_ext>
    <email>cschany@clinipace.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marin Cancer Care, Inc</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland, St. Joseph Medical Center, Cancer Institute</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute, Inc.</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute, Inc.</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent - Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore - Einstein Center for Cancer Care at Montefiore Medical Park</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Central New York, PC</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FDI Clinical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Suppression</keyword>
  <keyword>HR+</keyword>
  <keyword>HER2-</keyword>
  <keyword>Oncology</keyword>
  <keyword>Premenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

